Wedbush Reaffirms "Outperform" Rating for Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at Wedbush in a research note issued to investors on Monday, RTT News reports. They presently have a $9.00 price objective on the stock. Wedbush's target price would suggest a potential upside of 50.50% from the company's previous close.

HOWL has been the topic of several other research reports. JMP Securities restated a "market outperform" rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a research report on Monday.

Werewolf Therapeutics Trading Down 1.5 %

Werewolf Therapeutics stock traded down $0.09 during midday trading on Monday, hitting $5.98. 203,494 shares of the stock were exchanged, compared to its average volume of 234,111. The stock has a market capitalization of $259.22 million, a PE ratio of -5.49 and a beta of 0.71. The company has a fifty day simple moving average of $6.21 and a two-hundred day simple moving average of $4.67. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.10. The company had revenue of $1.50 million for the quarter, compared to analysts' expectations of $2.75 million. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. Equities research analysts anticipate that Werewolf Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Large investors have recently added to or reduced their stakes in the company. Financial Perspectives Inc increased its holdings in shares of Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company's stock valued at $26,000 after purchasing an additional 3,000 shares during the last quarter. Certuity LLC bought a new stake in shares of Werewolf Therapeutics during the fourth quarter worth approximately $39,000. Lighthouse Investment Partners LLC acquired a new position in shares of Werewolf Therapeutics in the fourth quarter valued at approximately $87,000. Denali Advisors LLC bought a new position in shares of Werewolf Therapeutics during the first quarter worth approximately $172,000. Finally, PFM Health Sciences LP lifted its holdings in shares of Werewolf Therapeutics by 35.6% during the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company's stock worth $13,387,000 after buying an additional 909,895 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company's stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.